Ivacaftor (benzenesulfonate)

• UNSPSC Description:

  Ivacaftor benzenesulfonate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.

• Target Antigen:

  Autophagy; CFTR

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Membrane Transporter/Ion Channel

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/ivacaftor-benzenesulfonate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(C1=CC=CC=C1)(O)=O.CC(C)(C2=C(C=C(C(C(C)(C)C)=C2)O)NC(C3=CNC4=C(C3=O)C=CC=C4)=O)C

• Molecular Weight:

  550.67

• References & Citations:

  [1]Delaunay JL, et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770). Hepatology. 2017 Feb;65(2):560-570|[2]Mutyam V, et al. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros. 2017 Jan;16(1):24-29|[3]Hadida S, et al. Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. J Med Chem. 2014 Dec 11;57(23):9776-9|[4]Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  1134822-09-5